SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5506 participants.

Also called NCT04418479

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 5,506 participants (enrolled count) (from the registry)
Sponsor
Joo-Yong Hahn (from the registry)
Registry
  • NCT NCT04418479
Other papers using this trial's data
  • Clopidogrel vs Aspirin According to Diabetes Mellitus: A Prespecified Analysis of the SMART-CHOICE 3 Trial JACC. Cardiovascular interventions, 2026-09-14 DOI, PubMed 42461194
  • Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial Lancet (London, England), 2025-04-12 DOI, PubMed 40174599

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04418479. Randomized; no masking; primary purpose treatment. Start 2020-08-10 (actual); primary completion 2024-10-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3
Acronym
SMART-CHOICE3
Intervention (Drug)
Aspirin
Intervention (Drug)
Clopidogrel
Lead sponsor
Joo-Yong Hahn (class: other)

Record details

Record id
cardio:ct-nct04418479
Content hash
0a9e5e9dbd31fb65b5d4bfe1ac6cc2c2394804629584d2cc4c7c85eefbbe7268